Skip to main content

Peer Review reports

From: Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus

Original Submission
17 Feb 2012 Submitted Original manuscript
5 Mar 2012 Author responded Author comments - Elizabeth Hussey
Resubmission - Version 2
5 Mar 2012 Submitted Manuscript version 2
9 Aug 2012 Reviewed Reviewer Report - David Boulton
15 Aug 2012 Reviewed Reviewer Report - Mark Fineman
22 Aug 2012 Reviewed Reviewer Report - Yutaka Seino
22 Jan 2013 Author responded Author comments - Elizabeth Hussey
Resubmission - Version 3
22 Jan 2013 Submitted Manuscript version 3
Resubmission - Version 4
Submitted Manuscript version 4
25 Jan 2013 Reviewed Reviewer Report - David Boulton
6 Feb 2013 Reviewed Reviewer Report - Yutaka Seino
11 Feb 2013 Reviewed Reviewer Report - Mark Fineman
22 Mar 2013 Author responded Author comments - Elizabeth Hussey
Resubmission - Version 5
22 Mar 2013 Submitted Manuscript version 5
9 Apr 2013 Reviewed Reviewer Report - Yutaka Seino
15 Apr 2013 Reviewed Reviewer Report - Mark Fineman
16 Apr 2013 Author responded Author comments - Elizabeth Hussey
Resubmission - Version 6
16 Apr 2013 Submitted Manuscript version 6
Publishing
18 Apr 2013 Editorially accepted
30 Apr 2013 Article published 10.1186/2050-6511-14-25

You can find further information about peer review here.

Back to article page